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Concerns about the Predictive Factors for Tumor Regression, 
Definition, and Management of Nonresponders, and Relapse of 
Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Related to 
Helicobacter pylori
Sun-Young Lee
Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea
  I read with interest the recent review article by Suzuki 
et al.
1 This paper helps gastroenterologists to understand 
the link between gastric mucosa-associated lymphoid tis-
sue (MALT) lymphoma and Helicobacter pylori ( H. pylori), 
but several questions remain unanswered: (i) the pre-
dictive factors for regression of gastric MALT lymphoma 
after  H. pylori eradication, (ii) the characteristic endo-
scopic findings, (iii) how to optimize the definition and 
managemnet of nonresponders, and (iv) how to manage 
the relapse and recurrence of these tumors.
  The first report in 1993
2 has been followed by numer-
ous reports of regression of MALT lymphoma after H. py-
lori eradication. However, not all gastric MALT lympho-
mas regress after H. pylori eradication, and thus three fac-
tors related to the prediction of tumor regression need to 
be considered: (i) the characteristics of gastric MALT 
lymphoma itself, (ii) the presence of H. pylori infection, 
and (iii) factors related to the host, such as the score on 
the international prognostic index and blood-test results. 
For example, even the location of the tumor has been 
mentioned as a predictive factor, with gastric MALT lym-
phomas on the proximal side being linked to autoim-
munity.
3 These proximal-side tumors progress very slowly 
and often fail to regress because they are linked to auto-
antigen responsive T cells.
3,4 In addition, histological fea-
tures of MALT lymphoma are known to be unresponsive 
to eradication therapy.
5
  An endoscopic apperance mimiking submucosal tumors 
and cobblestone like elevated lesions have been classified 
as polypoid gastric MALT lymphoma, and characterized as 
H. pylori-negative gastric MALT lymphoma.
6,7 Although 
Suzuki et al. described this briefly in their review,
1 H. py-
lori negativity needs to be defined. Since there is no sin-
gle gold-standard methods for diagnosing H. pylori in-
fection, the combination of several diagnostic methods in-
cluding  H. pylori IgG antibody, histology, culture, im-
munohistochemistry, PCR, and the urease breath test is 
c o n s i d e r e d  t o  b e  s u i t a b l e  f o r  c o n f i r m i n g  H. pylori nega-
tivity.
8 In addition, the characteristics of H. pylori-negative 
gastric MALT lymphoma should be managed based on 
previous reports.
9 Put simply, the treatment should differ 
from  H. pylori eradication in these H. pylori-negative gas-
tric MALT lymphoma due to the absence of H. pylori. 
However, these lymphomas also respond to antibiotic 
treatment in both the stomach and other parts of the gas-
trointestinal tracts.
10 What mechanism underlies this phe-
nomenon? Does this represent a clue for a false-negative 
diagnosis of H. pylori infection? What would be the possi-
ble hypothesis based on previous reports?
  On the other hand, non-H. pylori helicobacters related to 
M A L T  l y m p h o m a  s h o u l d  a l s o  b e  c o n s i d e r e d ,  s u c h  a s  H. 
helimannii and H. felis.
11 Interestingly, some of these re-
gress merely after the application of first-line H. pylori 
eradication therapy.
12 In addition, these organisms are de-
tected in both gastric and rectal lymphomas.
13
  Optimizing the definition and management of nonres-
ponders requires consideration of three issues: (i) the 
minimum observation period needed to define regression, 
(ii) interpretating discrepancies between the histologic 
and endoscopic regression, and (iii) choosing between a 
“wait and see strategy” and a second-line treatment such 
as gastrectomy, chemotherapy, and radiotherapy. Alth-236   Gut and Liver, Vol. 3, No. 3, September 2009
ough a Japanese study adressed the last issue,
14 the opti-
mal strategy remains unclear. In addition to the definition 
and management, the relapse and recurrence of gastric 
MALT lymphoma after successful regression on H. pylori 
eradication also need to be clarified. There are some re-
ports of the development of high-grade tumor (diffuse 
large B-cell lymphoma) or gastric adenocarcinoma after 
successful regression of gastric MALT lymphoma. What 
would be the mechanisms and prognostic factors in such 
tumors?
  In summary, answers to the above questions that arose 
when I read the review by professor Suzuki and col-
leagues would be of considerable interest to readers of 
Gut and Liver. There are already several interesting pub-
lished papers written by Japanese authors that strengthen 
our knowledge in this field, and I strongly believe that 
addressing the above issues would greatly increase the in-
terest in their review article. 
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